Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases

21-Sep-2005

Welichem Biotech Inc. announced that the Australian Patent Office has granted the Company a patent (No.780700) covering compounds in the WBI-1000 series that are useful in the treatment of inflammatory/auto-immune diseases such as psoriasis and inflammatory bowel disease.

A total of 16 claims covering novel compounds, pharmaceutical composition and use were granted with a term lasting to December 2019. This is the first patent issued for the Company's WBI-1000 series of compounds in a cluster of national applications pending in jurisdictions including Australia, Canada, China, Europe, Japan, Korea and the United States.

"This latest patent strengthens the Company's growing proprietary position in pre-targeted therapies that seek to address unmet medical needs in inflammatory/autoimmune diseases," said John Webster, President & CEO of Welichem. "It also provides intellectual property protection for our lead product, WBI-1001, part of a group of pharmaceutical compounds from symbiotic organisms that have great potential to treat a number of diseases and disorders," he added. The Company currently plans to begin formal clinical testing of the drug in early 2006.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance